Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

BACKGROUND: In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Intermittent therapy with 3-month breaks may be beneficial for patients’ quali...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribi, Karin, Luo, Weixiu, Colleoni, Marco, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L., Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734915/
https://www.ncbi.nlm.nih.gov/pubmed/30967649
http://dx.doi.org/10.1038/s41416-019-0435-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734915/
https://www.ncbi.nlm.nih.gov/pubmed/30967649
http://dx.doi.org/10.1038/s41416-019-0435-4

Ejemplares similares